Acquired haemophilia A with a recalcitrant high-titre factor VIII inhibitor in the setting of interstitial lung disease

BMJ Case Rep. 2017 Jul 28;2017:bcr2017220932. doi: 10.1136/bcr-2017-220932.


Acquired haemophilia A (AHA) is a bleeding disorder that results from autoantibodies against factor VIII (FVIII). A 70-year-old man with a history of interstitial lung disease presented with spontaneous bleeding into his thigh. He had undetectable FVIII levels and a high-titre FVIII inhibitor (>2000ââ'¬â€°Bethesda units/mL) and was diagnosed with AHA. He had several relapses, required multiple haemostatic and immunosuppressive treatments but eventually achieved a stable remission after 2ââ'¬â€°years of therapy.Our patient matches the typical elderly male demographic of AHA. His relapsing course with remarkably high and persistent inhibitor titre highlights the need for close monitoring and aggressive upfront treatment. Whereas cyclophosphamide and steroids are often used first line in AHA, rituximab has also shown efficacy in refractory patients with high inhibitor levels. The FVIII and inhibitor concentration on presentation have been associated with treatment response and may be used as prognostic factors to tailor immunosuppressive regimens.

Keywords: Haematology (drugs And Medicines); Haematology (incl Blood Transfusion).

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibiotics, Antineoplastic / therapeutic use*
  • Flank Pain
  • Follow-Up Studies
  • Hemophilia A / complications
  • Hemophilia A / diagnosis*
  • Hemophilia A / drug therapy
  • Hemophilia A / physiopathology
  • Hemorrhage / drug therapy*
  • Hemorrhage / etiology
  • Humans
  • Lung Diseases, Interstitial / complications
  • Lung Diseases, Interstitial / physiopathology*
  • Male
  • Mycophenolic Acid / therapeutic use*
  • Remission Induction
  • Secondary Prevention / methods*
  • Thigh
  • Time Factors
  • Treatment Outcome


  • Antibiotics, Antineoplastic
  • Mycophenolic Acid

Supplementary concepts

  • Factor 8 deficiency, acquired